GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hard to Treat Diseases Inc (OTCPK:HTDS) » Definitions » Cash Flow from Operations

Hard to Treat Diseases (Hard to Treat Diseases) Cash Flow from Operations : $0.00 Mil (TTM As of . 20)


View and export this data going back to . Start your Free Trial

What is Hard to Treat Diseases Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in . 20, Hard to Treat Diseases's Net Income From Continuing Operations was $0.00 Mil. Its Depreciation, Depletion and Amortization was $0.00 Mil. Its Change In Working Capital was $0.00 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $0.00 Mil. And its Cash Flow from Others was $0.00 Mil. In all, Hard to Treat Diseases's Cash Flow from Operations for the three months ended in . 20 was $0.00 Mil.


Hard to Treat Diseases Cash Flow from Operations Historical Data

The historical data trend for Hard to Treat Diseases's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hard to Treat Diseases Cash Flow from Operations Chart

Hard to Treat Diseases Annual Data
Trend
Cash Flow from Operations

Hard to Treat Diseases Quarterly Data
Cash Flow from Operations

Hard to Treat Diseases Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Hard to Treat Diseases's Cash Flow from Operations for the fiscal year that ended in . 20 is calculated as:

Hard to Treat Diseases's Cash Flow from Operations for the quarter that ended in . 20 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in . 20 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hard to Treat Diseases  (OTCPK:HTDS) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Hard to Treat Diseases's net income from continuing operations for the three months ended in . 20 was $0.00 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Hard to Treat Diseases's depreciation, depletion and amortization for the three months ended in . 20 was $0.00 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Hard to Treat Diseases's change in working capital for the three months ended in . 20 was $0.00 Mil. It means Hard to Treat Diseases's working capital {id_Q12} from . 20 to . 20 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Hard to Treat Diseases's cash flow from deferred tax for the three months ended in . 20 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Hard to Treat Diseases's cash from discontinued operating Activities for the three months ended in . 20 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Hard to Treat Diseases's asset impairment charge for the three months ended in . 20 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Hard to Treat Diseases's stock based compensation for the three months ended in . 20 was $0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Hard to Treat Diseases's cash flow from others for the three months ended in . 20 was $0.00 Mil.


Hard to Treat Diseases Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Hard to Treat Diseases's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Hard to Treat Diseases (Hard to Treat Diseases) Business Description

Traded in Other Exchanges
N/A
Address
2655 Ulmerton Road, No. 338, Clearwater, FL, USA, 33762
Hard to Treat Diseases Inc operates medical and cosmetics company in Europe, and Mainland China. It is s also in the process of developing its own stem cell bank.

Hard to Treat Diseases (Hard to Treat Diseases) Headlines

No Headlines